Fig. 6From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyTime course of predicted change from baseline in clinical endpoints by plasma A Ab42/40 ratio and B p-tau181 change from baselineBack to article page